Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.8.0.1
Commitments and Contingencies - Additional Information (Detail)
1 Months Ended 3 Months Ended
Nov. 30, 2017
USD ($)
Oct. 31, 2017
Oct. 31, 2016
USD ($)
Mar. 31, 2018
USD ($)
Milestone
UFRF License Agreement [Member]        
Commitment And Contingencies [Line Items]        
Company's obligation to pay from percentage of selling price of product       5.00%
Company's obligation to pay from all revenue received from sublicenses       22.00%
One-time commercialization fee monthly amount for calculation       $ 5,000
Post-commercialization minimum royalty payments       50,000
One-time additional royalty payment would be due when total cumulative royalties paid to UFRF exceed amount       $ 2,000,000
One-time additional payment to UFRF as a percentage of total royalties due to UFRF       10.00%
Minimum annual maintenance payment on license agreement       $ 10,000
Quarterly maintenance payment to UFRF under installment plan       $ 2,500
Termination notice period       90 days
Texas A and M University License [Member]        
Commitment And Contingencies [Line Items]        
Company's obligation to pay from percentage of selling price of product       5.00%
Post-commercialization minimum royalty payments       $ 100,000
Initial payment to Texas A&M       5,000
Minimum consideration for the continuation of the license agreement       $ 15,000
Number of milestones achieved | Milestone       0
Texas A and M University License [Member] | Amendment [Member]        
Commitment And Contingencies [Line Items]        
Minimum consideration for the continuation of the license agreement     $ 25,000  
Texas A and M University License [Member] | Phase 1 Clinical Trial [Member]        
Commitment And Contingencies [Line Items]        
Date of milestone achievement under licensing agreement with Texas A&M       Jun. 01, 2019
Milestone payment under licensing agreement       $ 50,000
Texas A and M University License [Member] | Phase 2 Clinical Trial [Member]        
Commitment And Contingencies [Line Items]        
Date of milestone achievement under licensing agreement with Texas A&M       Jun. 01, 2022
Milestone payment under licensing agreement       $ 100,000
Texas A and M University License [Member] | Phase 3 Clinical Trial [Member]        
Commitment And Contingencies [Line Items]        
Date of milestone achievement under licensing agreement with Texas A&M       Jun. 01, 2025
Milestone payment under licensing agreement       $ 150,000
Texas A and M University License [Member] | Sale Of Licensed Technology [Member]        
Commitment And Contingencies [Line Items]        
Date of milestone achievement under licensing agreement with Texas A&M       Jun. 01, 2026
Milestone payment under licensing agreement       $ 400,000
Texas A and M University License [Member] | Minimum [Member]        
Commitment And Contingencies [Line Items]        
Company's obligation to pay from percentage of selling price of product       2.00%
Lantibiotic ECC [Member]        
Commitment And Contingencies [Line Items]        
Company's obligation to pay from percentage of selling price of product       10.00%
Company's obligation to pay from all revenue received from sublicenses 25.00%     25.00%
Number of milestones achieved | Milestone       0
Royalty rate based on percentage of net sales 10.00%      
Lantibiotic ECC [Member] | Scenario, Previously Reported [Member]        
Commitment And Contingencies [Line Items]        
Company's obligation to pay from all revenue received from sublicenses   50.00%    
Royalty rate based on percentage of product profit   25.00%    
Lantibiotic ECC [Member] | Regulatory Approval Application Milestone Event [Member]        
Commitment And Contingencies [Line Items]        
Milestone payment under licensing agreement       $ 25,000,000
Milestone measurement period       6 months
Lantibiotic ECC [Member] | New Indication Milestone Event [Member]        
Commitment And Contingencies [Line Items]        
Milestone payment under licensing agreement       $ 5,000,000
Milestone measurement period       6 months
Lantibiotic ECC [Member] | New Product Milestone Event [Member]        
Commitment And Contingencies [Line Items]        
Milestone payment under licensing agreement       $ 5,000,000
Milestone measurement period       6 months
Lantibiotic ECC [Member] | New Drug Application [Member]        
Commitment And Contingencies [Line Items]        
Milestone payment under licensing agreement $ 25,000,000      
Milestone measurement period 6 months      
Lantibiotic ECC [Member] | Minimum [Member]        
Commitment And Contingencies [Line Items]        
Advancement expended amount for lantibiotic program $ 1,200,000      
Oral Mucositis ECC [Member]        
Commitment And Contingencies [Line Items]        
Company's obligation to pay from percentage of selling price of product       12.00%
Company's obligation to pay from all revenue received from sublicenses 25.00%     25.00%
Number of milestones achieved | Milestone       0
Oral Mucositis ECC [Member] | Scenario, Previously Reported [Member]        
Commitment And Contingencies [Line Items]        
Company's obligation to pay from all revenue received from sublicenses   50.00%    
Oral Mucositis ECC [Member] | Regulatory Approval Application Milestone Event [Member]        
Commitment And Contingencies [Line Items]        
Milestone payment under licensing agreement       $ 27,500,000
Milestone measurement period       6 months
Oral Mucositis ECC [Member] | New Indication Milestone Event [Member]        
Commitment And Contingencies [Line Items]        
Milestone payment under licensing agreement       $ 5,000,000
Milestone measurement period       6 months
Oral Mucositis ECC [Member] | New Product Milestone Event [Member]        
Commitment And Contingencies [Line Items]        
Milestone payment under licensing agreement       $ 5,000,000
Milestone measurement period       6 months
Oral Mucositis ECC [Member] | New Product Application [Member]        
Commitment And Contingencies [Line Items]        
Milestone payment under licensing agreement $ 27,500,000      
Milestone measurement period 6 months      
Oral Mucositis ECC [Member] | Maximum [Member]        
Commitment And Contingencies [Line Items]        
Maturity of interest bearing promissory note       12 months